Treatment Options in Pediatric Behçet's Disease

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Behçet's disease is a rare, poorly understood vasculitis affecting all blood vessel types.
• It typically presents with oral/genital ulcers and uveitis, with higher prevalence along ancient trade routes.
• Pediatric onset occurs in up to 25% of cases, usually around puberty.

Purpose of the Study:

• To outline the importance of early intervention in Behçet's disease management.
• To highlight the need for multidisciplinary and tailored treatment approaches.
• To review current and emerging therapeutic strategies for Behçet's disease, including pediatric considerations.

Main Methods:

• Review of current literature on Behçet's disease pathophysiology and treatment.
• Analysis of clinical presentation, diagnostic challenges, and prognostic factors.
• Evaluation of established and novel pharmacological agents, including biologics and small molecules.

Main Results:

• Heterogeneous clinical presentation necessitates individualized treatment plans.
• Ocular, neurological, gastrointestinal, and vascular involvement indicate a poorer prognosis.
• While corticosteroids and conventional DMARDs are used, newer biologics (anti-TNF, IL-1, IL-6, IL-17 inhibitors) and small molecules (PDE4, JAK inhibitors) show promise, particularly for severe cases.

Conclusions:

• Effective Behçet's disease management requires early, aggressive, and multidisciplinary intervention.
• Treatment strategies must be tailored to disease severity, organ involvement, and patient age (especially in pediatrics).
• The expanding therapeutic landscape offers new hope, but challenges remain regarding pediatric-specific drug approvals and evidence.